North Carolina's biotechnology industry thrives on innovation, concentrating on the development of medical therapies, agricultural solutions, and genetic research. It comprises firms varying in size that offer products from gene therapies and immunotherapies to bioinformatics and agricultural applications. The state's renowned Research Triangle is pivotal, fostering collaboration among universities and biotech firms. As the demand for personalized medicine and sustainable agricultural practices rises, the state positions itself as a beacon for innovative biotech advancements, with companies continuously pushing the envelope. The industry is characterized by rapid growth, attracting substantial investments and excelling in cutting-edge research.

The companies on this list showcase North Carolina's remarkable biotechnology sector. They vary in size, from small ventures to large-scale operations, and have been formed over the past two decades, indicating robust growth. Predominantly based in cities like Durham and Morrisville, these companies specialize in areas like gene therapy, RNA-based treatments, and engineered pharmaceuticals. With a blend of corporate ownership and venture-backed firms, they collectively represent a forward-thinking approach to healthcare and agricultural biotechnologies, responding to critical challenges in human health and environmental sustainability.

Read on to discover more about North Carolina's biotechnology companies.

Top 23 Biotechnology Companies in North Carolina

1. FUJIFILM Diosynth Biotechnologies

• Website: fujifilmdiosynth.com
• Ownership type: Corporate
• Headquarters: Morrisville, North Carolina, United States (USA)
• Employee distribution: Denmark 43%, United States (USA) 40%, United Kingdom (UK) 17%
• Latest funding: $890.0M, August 2019
• Founded year: 2011
• Headcount: 1001-5000
• LinkedIn: fujifilm-diosynth-biotechnologies

FUJIFILM Diosynth Biotechnologies is a biotechnology company based in Morrisville, North Carolina, specializing in contract development and manufacturing services for biologics, vaccines, and advanced therapies. Founded in 2011, the company has quickly established itself as a key player in the biotechnology sector. It partners with pharmaceutical and biotechnology firms to provide expertise in current Good Manufacturing Practices (cGMP), ensuring that products are delivered safely and effectively. With a workforce of over 5,000 employees distributed across facilities in the United States, Denmark, the United Kingdom, and Japan, FUJIFILM Diosynth Biotechnologies supports clients through all phases of drug development, from pre-clinical studies to commercialization. The company has made significant investments in expanding its capabilities, including a recent $890 million funding round aimed at enhancing its manufacturing capacity. This strategic focus on growth and innovation underscores its relevance in the biotechnology industry.

2. AskBio Inc.

• Website: askbio.com
• Ownership type: Corporate
• Headquarters: Durham, North Carolina, United States (USA)
• Employee distribution: United States (USA) 75%, United Kingdom (UK) 14%, France 6%, Other 5%
• Latest funding: $2.0B, October 2020
• Founded year: 2001
• Headcount: 501-1000
• LinkedIn: askbio

AskBio Inc., also known as Asklepios BioPharmaceutical, Inc., is a biotechnology company based in Durham, North Carolina. Established in 2001, AskBio focuses on gene therapy, utilizing its advanced AAV technology to develop innovative treatments for genetic diseases. The company collaborates with researchers and healthcare providers to create life-saving therapies that address significant unmet medical needs across various genetic conditions. AskBio has a strong clinical pipeline that includes programs targeting neuromuscular disorders, central nervous system diseases, cardiovascular conditions, and ultra-rare genetic diseases. In 2020, AskBio secured $2 billion in funding, underscoring its financial strength and commitment to advancing genetic medicine. The company also acquired Synpromics, a leader in synthetic promoter technology, further enhancing its capabilities in gene therapy. With a dedicated team and a focus on patient care, AskBio is positioned to make a substantial impact in the biotechnology field.

3. Ribometrix Inc.

• Website: ribometrix.com
• Ownership type: Venture Capital
• Headquarters: Durham, North Carolina, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $7.8M, September 2019
• Founded year: 2014
• Headcount: 11-50
• LinkedIn: ribometrix

Ribometrix Inc., founded in 2014 and based in Durham, North Carolina, is a biotechnology firm that specializes in drug discovery and development with a focus on RNA biology. The company aims to create small molecule therapeutics that can effectively target and modulate RNA to prevent the production of disease-causing proteins. Ribometrix's innovative platform allows them to tackle complex diseases, including various forms of cancer, central nervous system disorders, and autoimmune diseases. They have developed a comprehensive pipeline of drug candidates and have engaged in partnerships with other pharmaceutical companies to enhance their research capabilities. Ribometrix has received significant funding, totaling $7.8 million as of September 2019, which supports their ongoing research and development efforts. Their unique approach to drug discovery positions them as a noteworthy entity in the biotechnology industry.

4. Immorna

• Website: immorna.com
• Ownership type: Private Equity
• Headquarters: Morrisville, North Carolina, United States (USA)
• Employee distribution: United States (USA) 83%, China 17%
• Latest funding: Other (Grant), August 2024
• Founded year: 2019
• Headcount: 51-200
• LinkedIn: immorna

Immorna is a biotechnology company based in Morrisville, North Carolina, specializing in RNA-based therapeutics and vaccines. Founded in 2019, the company has developed a strong contract development and manufacturing organization (CDMO) that supports innovative RNA platforms for drug development. Immorna's services cater to pharmaceutical and research organizations, facilitating clinical trials and commercial applications. The company has built a comprehensive platform for RNA synthesis, purification, and analytical testing, which is essential for advancing their pipeline of drug candidates. Immorna's research spans various therapeutic areas, including cancer immunotherapy, infectious diseases, and rare genetic disorders. They have made significant strides in their clinical programs, receiving FDA IND clearance for multiple candidates, which underscores their active engagement in the biotechnology field. Immorna's leadership team comprises seasoned professionals with extensive experience in biotech and pharmaceuticals, further enhancing their credibility and operational capacity.

5. BioCytics Inc

• Website: biocytics.com
• Ownership type: Private
• Headquarters: Huntersville, North Carolina, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Other (Grant), $100,000, October 2024
• Founded year: 2005
• Headcount: 11-50
• LinkedIn: biocytics-inc.

BioCytics Inc, founded in 2005 and based in Huntersville, North Carolina, is a biotechnology company dedicated to advancing cancer treatment through immunotherapy and cellular therapies. The company operates a Human Applications Laboratory that supports the development of novel therapies and personalized medicine solutions. BioCytics offers a range of services, including cGMP manufacturing, clinical trial management, and laboratory diagnostics, catering to pharmaceutical companies and research institutions. Their focus on innovative treatments for cancer patients is complemented by their involvement in clinical trials and biospecimen banking. Recently, BioCytics secured a grant of $100,000, reflecting their active engagement in research and development within the biotechnology sector.

6. Hatteras Venture Partners

• Website: hatterasvp.com
• Ownership type: Private
• Headquarters: Durham, North Carolina, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 2000
• Headcount: 11-50
• LinkedIn: hatteras-venture-partners

Hatteras Venture Partners, based in Durham, North Carolina, is a private venture capital firm established in 2000. The firm specializes in healthcare innovation, focusing on early-stage companies that are developing transformative therapies and medical technologies. With a team of experienced investors, Hatteras aims to build companies that improve patient outcomes and enhance the healthcare experience. Their portfolio includes a range of companies involved in biopharma, medical devices, and healthcare IT, showcasing their commitment to advancing the biotechnology sector. Hatteras employs a risk-mitigated investment approach, leveraging their extensive industry knowledge to support the growth of their portfolio companies. They are recognized for their contributions to the healthcare innovation ecosystem, particularly in the Southeast region of the United States.

7. Inceptor Bio

• Website: inceptor.bio
• Ownership type: Corporate
• Headquarters: Morrisville, North Carolina, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series A, $21.0M, February 2025
• Founded year: 2020
• Headcount: 11-50
• LinkedIn: inceptor-bio

Inceptor Bio, based in Morrisville, North Carolina, is a biotechnology company founded in 2020. The firm specializes in advanced cell therapies aimed at treating solid tumors, which represent a major challenge in cancer treatment. Inceptor Bio is developing innovative solutions such as the OUTLAST™ CAR T platform and CAR-M therapies, which are designed to enhance the effectiveness of immunotherapy against solid tumors. Their primary customers include healthcare providers and research institutions seeking cutting-edge cancer therapies. The company has recently raised $21 million in Series A funding, which underscores its growth potential and the interest it has garnered from investors. Inceptor Bio is actively involved in the biotechnology community, presenting its research at major conferences and collaborating with academic institutions to advance its therapeutic offerings.

8. Locus Biosciences, Inc.

• Website: locus-bio.com
• Ownership type: Venture Capital
• Headquarters: Morrisville, North Carolina, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series B, $35.0M, May 2022
• Founded year: 2015
• Headcount: 51-200
• LinkedIn: locus-biosciences-inc.

Locus Biosciences, Inc., founded in 2015 and based in Morrisville, North Carolina, is a biotechnology firm dedicated to developing engineered bacteriophage therapies. These therapies target bacterial infections and immunologic diseases, particularly those caused by antibiotic-resistant strains. The company utilizes advanced technologies, including synthetic biology and AI-driven predictive modeling, to create precision medicines. Locus has a robust pipeline with several clinical-stage products, including LBP-EC01, aimed at treating urinary tract infections caused by multidrug-resistant E. coli. The company has received significant funding, including a $35 million Series B round in May 2022, and has established partnerships with organizations like BARDA and CARB-X to advance its clinical programs. Locus's innovative approach and commitment to addressing unmet medical needs position it as a notable player in the biotechnology sector.

9. Kineticos Life Sciences

• Website: kineticos.com
• Ownership type: Private
• Headquarters: Raleigh, North Carolina, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 2012
• Headcount: 1-10
• LinkedIn: kineticos-life-sciences

Kineticos Life Sciences, founded in 2012 and based in Raleigh, North Carolina, operates as a private investment firm with a strong focus on the life sciences sector. The company partners with early-stage biotechnology and medical technology firms, providing both investment and consulting services. Kineticos aims to help these companies navigate the complexities of drug development and commercialization. Their investment strategy targets significant unmet medical needs, particularly in oncology, antimicrobial resistance, and rare diseases. Kineticos also engages in the creation of new companies through their Foundry model, which fosters innovation and accelerates the development of therapies. Their portfolio includes a range of companies that are working on cutting-edge solutions in the biotechnology space, demonstrating their active involvement in shaping the future of healthcare.

10. Bamboo Therapeutics, Inc. a wholly owned subsidiary of Pfizer Inc.

• Website: bambootherapeutics.com
• Ownership type: Corporate
• Headquarters: Chapel Hill, North Carolina, United States (USA)
• Latest funding: $654.0M, August 2016
• Founded year: 2014
• Headcount: 11-50
• LinkedIn: bamboo-therapeutics

Bamboo Therapeutics, Inc., a wholly owned subsidiary of Pfizer Inc., is based in Chapel Hill, North Carolina. Founded in 2014, the company is dedicated to the development of gene therapies aimed at treating rare diseases. Its work is particularly focused on innovative approaches to address significant medical needs that are often overlooked by larger pharmaceutical companies. Bamboo Therapeutics leverages Pfizer's extensive resources and expertise in drug development, which enhances its capabilities in research and clinical trials. The company has received substantial funding, totaling $654 million in 2016, which underscores its commitment to advancing gene therapy solutions. Through its specialized focus, Bamboo Therapeutics plays a crucial role in the biotechnology industry, contributing to the evolution of treatment options for patients with rare conditions.

11. Tune Therapeutics

• Website: tunetx.com
• Ownership type: Venture Capital
• Headquarters: Durham, North Carolina, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series B, $175.0M, January 2025
• Founded year: 2020
• Headcount: 51-200
• LinkedIn: tunetx

Tune Therapeutics, founded in 2020 and based in Durham, North Carolina, is a biotechnology company specializing in genetic medicine and epigenomics. The company is dedicated to developing innovative therapies that leverage their proprietary TEMPO platform, which allows for precise regulation of gene expression without altering the DNA sequence. This technology aims to tackle chronic and age-related diseases, providing advanced solutions for healthcare providers and researchers. Tune Therapeutics has attracted significant venture capital funding, with a recent Series B round raising $175 million in January 2025. This financial backing underscores the company's potential and the interest in their approach to gene and cell therapies.

12. KBI Biopharma

• Website: kbibiopharma.com
• Ownership type: Venture Capital
• Headquarters: Durham, North Carolina, United States (USA)
• Employee distribution: United States (USA) 88%, Switzerland 12%
• Latest funding: December 2016
• Founded year: 1996
• Headcount: 1001-5000
• LinkedIn: kbi-biopharma

KBI Biopharma, founded in 1996 and based in Durham, North Carolina, is a biopharmaceutical development and manufacturing company. They provide a wide range of services that include cell line development, process development, analytical development, and both clinical and commercial manufacturing. KBI Biopharma serves pharmaceutical and biotechnology companies, assisting them in navigating the complexities of drug development while ensuring adherence to regulatory standards. With a workforce of over 1,600 employees, the company operates facilities in the United States and Europe, emphasizing their global reach. Their proprietary technologies, such as the SUREtechnology Platform™ and PUREplatform™, enhance their capabilities in producing biologics efficiently and effectively. KBI Biopharma's focus on high-quality standards and customer collaboration underscores their commitment to advancing biopharmaceutical solutions.

13. AgBiome

• Website: agbiome.com
• Ownership type: Venture Capital
• Headquarters: Durham, North Carolina, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series D, $116.0M, September 2021
• Founded year: 2012
• Headcount: 51-200
• LinkedIn: agbiome

AgBiome is an agricultural biotechnology company based in Durham, North Carolina, founded in 2012. The company specializes in creating microbial products aimed at crop protection, focusing on sustainable solutions to help farmers manage crop diseases. Their product lineup includes fungicides like Howler and Theia, which are designed to replace traditional synthetic chemicals with more environmentally friendly alternatives. AgBiome's proprietary GENESIS platform enables the identification and development of effective microbial strains, enhancing their product offerings. The company has attracted substantial investment, raising $116 million in a Series D funding round in September 2021, which underscores its potential and relevance in the biotechnology sector. AgBiome's commitment to sustainability and innovation positions it as a noteworthy player in the agricultural biotechnology field.

14. Zymtronix

• Website: zymtronix.com
• Ownership type: Venture Capital
• Headquarters: Durham, North Carolina, United States (USA)
• Latest funding: Other (Debt), $2.0M, December 2021
• Founded year: 2013
• Headcount: 11-50
• LinkedIn: zymtronix-catalytic-systems

Zymtronix, founded in 2013 and based in Durham, North Carolina, specializes in enzyme technology and bioconversion processes. The company aims to make rare molecules economically accessible by utilizing multiple enzymes to produce target molecules that traditional methods struggle to achieve. Their technology not only maximizes substrate conversions but also addresses product concentration limitations and purification costs. Zymtronix serves a variety of industries, including pharmaceuticals, agriculture, cosmetics, and nutrition, providing solutions that enhance product offerings through advanced enzyme applications. The company has secured funding, with a notable amount of $2 million in December 2021, indicating investor confidence in their innovative approach and potential for growth. With a team of experienced professionals, Zymtronix is positioned to accelerate product development and deliver sustainable outcomes across its sectors of operation.

15. Life Edit Therapeutics

• Website: lifeeditinc.com
• Ownership type: Private
• Headquarters: Durham, North Carolina, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 2017
• Headcount: 51-200
• LinkedIn: lifeedit

Life Edit Therapeutics, based in Durham, North Carolina, is a biotechnology firm founded in 2017. The company specializes in gene editing technologies, focusing on developing solutions for genetic disorders. Life Edit offers a range of products, including RNA-guided nucleases and therapeutic delivery systems, aimed at enhancing the therapeutic development pipelines of biotech and pharmaceutical companies. Their innovative gene editing platform allows for precise targeting of genomic sequences, enabling the development of therapies for complex genetic diseases. Life Edit is part of the ElevateBio ecosystem, which integrates various enabling technologies and manufacturing capabilities to accelerate the delivery of transformative genetic medicines. The company actively seeks partnerships with other biotech firms to advance their therapeutic approaches, demonstrating their commitment to collaboration in the industry.

16. Parexel

• Website: parexel.com
• Ownership type: Private Equity
• Headquarters: Durham, North Carolina, United States (USA)
• Employee distribution: India 34%, United States (USA) 17%, Romania 5%, Other 44%
• Latest funding: $8.5B, July 2021
• Founded year: 1983
• Headcount: 10001+
• LinkedIn: parexel

Parexel International, founded in 1983 and based in Durham, North Carolina, is a prominent clinical research organization (CRO) specializing in biopharmaceutical services. With over 20,000 employees globally, Parexel assists biopharmaceutical companies in navigating the complexities of drug development. Their services range from conducting Phase I to IV clinical trials to providing regulatory consulting, which helps expedite the drug approval process. Parexel's expertise spans various therapeutic areas, including oncology, neuroscience, and rare diseases, and they leverage advanced technologies and patient engagement strategies to enhance trial efficiency. The company has received significant funding, amounting to $8.5 billion in 2021, underscoring its financial backing and commitment to innovation in the clinical research space.

17. Eremid Genomic Services

• Website: eremid.com
• Ownership type: Corporate
• Headquarters: Kannapolis, North Carolina, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $3.0M, June 2023
• Founded year: 2019
• Headcount: 11-50
• LinkedIn: eremid

Eremid Genomic Services, based in Kannapolis, North Carolina, is a biotechnology firm that specializes in genomic research services. Founded in 2019, the company has carved out a niche by providing tailored solutions in RNA sequencing, microbiome analysis, and bioinformatics. Their services cater to clients in the AgBiotech, Food & Nutrition, and Human Health sectors, aiming to enhance research capabilities and improve health outcomes through cutting-edge genomic technologies. Eremid's commitment to quality is underscored by their CLIA certification and CAP accreditation, ensuring that they meet high standards in clinical and research applications. The company has also recently secured $3 million in funding, indicating strong investor confidence and potential for future growth. Eremid's focus on customized contract research services positions it as a valuable partner for organizations seeking to advance their genomic research initiatives.

18. Isolere Bio By Donaldson

• Website: isolerebio.com
• Ownership type: Corporate
• Headquarters: Durham, North Carolina, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: February 2023
• Founded year: 2017
• Headcount: 11-50
• LinkedIn: isolere-bio

Isolere Bio By Donaldson, founded in 2017 and based in Durham, North Carolina, is a biotechnology firm focused on bioprocessing solutions for the life sciences sector. The company specializes in developing innovative reagents aimed at enhancing the purification and manufacturing processes of viral vectors, which are essential for gene therapies and vaccines. Their flagship products, IsoTag™ AAV and IsoTag™ LV, utilize a chromatography-free approach to achieve high yields and purity in a streamlined manner. This technology is particularly beneficial for biotechnology and pharmaceutical companies looking to improve therapeutic development timelines and manufacturing efficiency. In February 2023, Isolere Bio was acquired by Donaldson Company, which has allowed them to leverage Donaldson's extensive experience in filtration solutions to further enhance their offerings in biopharmaceutical applications. The company is committed to accelerating the development of life-changing therapies and improving global access to these medicines.

19. Metabolon, Inc.

• Website: metabolon.com
• Ownership type: Venture Capital
• Headquarters: Morrisville, North Carolina, United States (USA)
• Employee distribution: United States (USA) 84%, United Kingdom (UK) 6%, Italy 2%, Other 8%
• Latest funding: Other (Grant), June 2024
• Founded year: 2000
• Headcount: 201-500
• LinkedIn: metabolon

Metabolon, Inc., founded in 2000 and based in Morrisville, North Carolina, is a biotechnology company that specializes in metabolomics. The firm provides advanced biomarker discovery and analysis services tailored for biopharma, academic, and healthcare organizations. Their offerings include both targeted and untargeted metabolomics panels, bioinformatics tools, and consulting services. With a team of over 192 employees, including 45 PhDs, Metabolon has completed more than 10,000 projects and contributed to over 3,000 publications. Their technology allows clients to gain insights into metabolic processes, which is essential for supporting drug development and enhancing research outcomes. Metabolon has also been involved in various applications, including precision medicine, population health studies, and clinical drug development, showcasing their relevance in the biotechnology industry.

20. Inhalon Biopharma

• Website: inhalon.com
• Ownership type: Venture Capital
• Headquarters: Durham, North Carolina, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Other (Grant), $2.0M, November 2022
• Founded year: 2018
• Headcount: 1-10
• LinkedIn: inhalon-biopharma

Inhalon Biopharma, founded in 2018 and based in Durham, North Carolina, is a clinical-stage biotechnology company dedicated to developing inhaled antibody treatments for acute respiratory infections. The company is pioneering a unique platform that allows for the direct delivery of antibodies to the lungs, targeting conditions such as respiratory syncytial virus (RSV), influenza, and SARS-CoV-2. Inhalon's approach aims to provide effective, self-administered treatments that can be used at home, addressing a significant gap in current therapeutic options. The company has received substantial funding, including a $7 million grant from the U.S. Army Medical Research and Development Command and a $2 million grant from the National Institutes of Health, to support the development of its inhaled therapies. Inhalon is actively advancing its product pipeline, which includes several candidates currently in clinical trials, showcasing its commitment to innovation in the biotechnology field.

21. Oerth Bio

• Website: oerthbio.com
• Ownership type: Venture Capital
• Headquarters: Durham, North Carolina, United States (USA)
• Employee distribution: United States (USA) 93%, United Kingdom (UK) 7%
• Latest funding: $55.0M, February 2020
• Founded year: 2019
• Headcount: 11-50
• LinkedIn: oerth-bio

Oerth Bio, founded in 2019 and based in Durham, North Carolina, is an agricultural biotechnology company dedicated to developing innovative solutions for crop protection, plant resilience, and health and nutrition. The company leverages PROTAC technology, which allows for targeted protein modulation to enhance agricultural practices. This technology aims to improve crop yield and quality while minimizing environmental impact. Oerth Bio operates primarily in the United States, with a small presence in the United Kingdom. The company has received significant funding, totaling $55 million, which underscores its potential and the interest it has garnered from investors. Oerth Bio's focus on sustainable agricultural practices positions it as a forward-thinking entity in the biotechnology sector, addressing the needs of farmers and agricultural businesses.

22. ZenBio, A BioIVT Company

• Website: zen-bio.com
• Ownership type: Corporate
• Headquarters: Durham, North Carolina, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: August 2024
• Founded year: 1995
• Headcount: 11-50
• LinkedIn: zenbio-inc

ZenBio, A BioIVT Company, established in 1995, is a biotechnology firm located in Durham, North Carolina, specifically in the Research Triangle Park area. This region is known for its concentration of biotech and pharmaceutical companies. ZenBio specializes in providing research products and services that focus on human health, particularly in the areas of obesity, diabetes, and cardiovascular disease. Their product line includes biological products, cell culture tools, and research kits designed for scientists and researchers in the biotechnology and pharmaceutical industries. ZenBio's commitment to supporting research in metabolic diseases is evident in their extensive catalog, which features human cells, serum products, and specialized research kits. The company also engages with local and national charities, demonstrating a commitment to community involvement. While ZenBio has not reported any recent funding, their established presence and specialized offerings make them a notable player in the biotechnology sector.

23. Kriya Therapeutics, Inc.

• Website: kriyatx.com
• Ownership type: Private
• Headquarters: Morrisville, North Carolina, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 2019
• Headcount: 51-200
• LinkedIn: kriyatherapeutics

Kriya Therapeutics, Inc. is a biotechnology firm based in Morrisville, North Carolina, founded in 2019. The company specializes in the development of gene therapies aimed at treating various medical conditions, including diabetes, neurological disorders, and eye diseases. Kriya's product pipeline features several promising candidates, such as KRIYA-839 for diabetes, KRIYA-586 for Thyroid Eye Disease, and KRIYA-748 for trigeminal neuralgia. Their approach focuses on creating one-time treatments that could significantly improve patient outcomes and reduce the burden of chronic therapies. Kriya operates with a mission to make gene therapies accessible to a broader population, reflecting their commitment to addressing significant health challenges. The company is backed by notable healthcare and technology investors, which underscores its potential in the biotechnology field.

Biotechnology Insights: Key Companies in North Carolina

Want to Find More Biotechnology Companies?

With Inven you'll also get to know the company's:

• Detailed Ownership: Who owns the company? Is it a public or private company? What is the ownership structure?
• Contact data: Who are the founders and CEO's? What are their emails and phone numbers?
• Financials: How do these companies perform financially? What are their revenues and profit margins?

...and a lot more!